Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand

Kanami Itoh, Nobuyuki Udagawa, Takenobu Katagiri, Shunichiro Iemura, Naoto Ueno, Hisataka Yasuda, Kanji Higashio, Julian M.W. Quinn, Matthew T. Gillespie, T. John Martin, Tatsuo Suda, Naoyuki Takahashi

Research output: Contribution to journalArticleResearchpeer-review

203 Citations (Scopus)

Abstract

Bone is a major storage site for TGFβ superfamily members, including TGFβ and bone morphogenetic proteins. It is believed that these cytokines are released from bone during bone resorption. Recent studies have shown that both RANKL and macrophage colony-stimulating factor are two essential factors produced by osteoblasts for inducing osteoclast differentiation. In the present study we examined the effects of bone morphogenetic protein-2 on osteoclast differentiation and survival supported by RANKL and/or macrophage colony-stimulating factor. Mouse bone marrow-derived macrophages differentiated into osteoclasts in the presence of RANKL and macrophage colony-stimulating factor. TGFβ superfamily members such as bone morphogenetic protein-2, TGFβ, and activin A markedly enhanced osteoclast differentiation induced by RANKL and macrophage colony-stimulating factor, although each cytokine alone failed to induce osteoclast differentiation in the absence of RANKL. Addition of a soluble form of bone morphogenetic protein receptor type IA to the culture markedly inhibited not only osteoclast formation induced by RANKL and bone morphogenetic protein-2, but also the basal osteoclast formation supported by RANKL alone. Either RANKL or macrophage colony-stimulating factor stimulated the survival of purified osteoclasts. Bone morphogenetic protein-2 enhanced the survival of purified osteoclasts supported by RANKL, but not by macrophage colony-stimulating factor. Both bone marrow macrophages and mature osteoclasts expressed bone morphogenetic protein-2 and bone morphogenetic protein receptor type IA mRNAs. An EMSA revealed that RANKL activated nuclear factor-κB in purified osteoclasts. Bone morphogenetic protein-2 alone did not activate nuclear factor-κB, but rather inhibited the activation of nuclear factor-κB induced by RANKL in purified osteoclasts. These findings suggest that bone morphogenetic protein-mediated signals cross-communicate with RANKL-mediated ones in inducing osteoclast differentiation and survival. The enhancement of RANKL-induced survival of osteoclasts by bone morphogenetic protein-2 appears unrelated to nuclear factor-κB activation.

Original languageEnglish
Pages (from-to)3656-3662
Number of pages7
JournalEndocrinology
Volume142
Issue number8
DOIs
Publication statusPublished - 1 Jan 2001
Externally publishedYes

Cite this